Return to homepagePandemic Pact

Mining the host-pathogen interface to deliver a drug pipeline for treating intractable and emerging infections

  • Funded by National Health and Medical Research Council (NHMRC)
  • Total publications:0 publications

Grant number: GA201458

Grant search

Key facts

  • Disease

    Disease X

  • Start & end year

    2022
    2026

  • Known Financial Commitments (USD)

    $3,605,995

  • Funder

    National Health and Medical Research Council (NHMRC)

  • Principal Investigator

    N/A

  • Research Location

    Australia

  • Lead Research Institution

    The University of Queensland

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Emerging viruses and antibiotic-resistant superbugs are the most important challenge to human health in the 21st century. New viruses such as SARS-CoV2 and Zika, as well as antibiotic resistant superbugs, emerge regularly and rapidly, urgently requiring new therapies. Our multidisciplinary Synergy team has demonstrated success in drug development and will create new drugs to avert the imminent global health disaster posed by emerging viruses and superbugs.